China Animal Testing Law Review: What It Means for Cosmetics

Date:

Share post:

China Animal Testing Law Review: What It Means for Cosmetics

China’s animal testing regulations for cosmetics have undergone the most significant transformation since 2021, with over 12,000 non-special-use cosmetic products now eligible for exemption from mandatory animal testing annually—a figure that represents 78% of all imported cosmetic filings in 2024. This review examines the current legal landscape, enforcement realities, and strategic implications for foreign cosmetic brands entering or expanding in China.

Regulatory Evolution: From Mandatory Testing to Managed Exemptions

China’s dual-track system for 化妆品 (cosmetics, huàzhuāng pǐn) distinguishes between 特殊化妆品 (special-use cosmetics, tèshū huàzhuāng pǐn) and 普通化妆品 (general cosmetics, pǔtōng huàzhuāng pǐn). Prior to the 2021 化妆品监督管理条例 (Cosmetics Supervision and Administration Regulation, huàzhuāng pǐn jiāndū guǎnlǐ tiáolì), all imported cosmetics required animal testing for registration. The reform reduced this burden by 40% for general cosmetics in pilot zones, but special-use products—including sunscreens, hair dyes, and anti-aging creams—still face mandatory pre-market testing.

By early 2024, 30+ provincial-level regions had adopted exemption programs for general cosmetics, covering approximately 5,000 foreign brands. However, the National Medical Products Administration (NMPA) maintains that any cosmetic containing new ingredients not listed in the 已使用化妆品原料目录 (Existing Cosmetic Ingredient Inventory, yǐ shǐyòng huàzhuāng pǐn yuánliào mùlù) is ineligible for exemption, requiring both animal testing and human safety trials. This creates a critical bottleneck for innovative formulations.

Who Is Exempt? The “General” vs “Special” Distinction

Understanding the boundary between exempt and non-exempt products is the single most important compliance decision for foreign executives.

Category Pre-2021 Requirement 2024 Requirement Testing Cost (RMB) Timeline
General Cosmetics (e.g., moisturizers, cleansers) Mandatory animal testing Exempt if in inventory and non-functional claim 0 (exemption) vs 150,000–300,000 (testing) 2–4 months (exemption) vs 8–12 months (testing)
Special-Use Cosmetics (e.g., sunscreen, anti-aging) Mandatory animal testing Mandatory animal testing still required 400,000–800,000 per product 12–18 months
New Cosmetic Ingredients Prohibited without testing Animal testing required + human safety trials 1,000,000–3,000,000 per ingredient 18–24 months
Children’s Cosmetics Mandatory animal testing Mandatory animal testing still required 300,000–600,000 per product 10–14 months

The cost differential is stark: brands qualifying for exemption save 150,000–300,000 RMB per SKU and reduce time-to-market by 6–10 months. However, the exemption is conditional on the product containing no new ingredients and making no therapeutic or functional claims. Any product that claims “whitening,” “anti-wrinkle,” or “sunscreen protection” automatically triggers special-use classification.

Enforcement Reality: Customs, NMPA, and Local FDA Offices

While national policy has liberalized, enforcement varies significantly by port of entry. In 2024, customs authorities in Shanghai and Guangzhou rejected 14% of exemption claims due to documentation errors—primarily incomplete ingredient declarations and failure to prove that all ingredients are in the Existing Cosmetic Ingredient Inventory. Brands relying on the exemption without rigorous pre-filing audits face rejection rates as high as 1 in 7.

The 国家药品监督管理局 (National Medical Products Administration, NMPA, guójiā yàopǐn jiāndū guǎnlǐ jú) has also increased random sampling of exempted products. In 2023, 1,200 samples were tested for compliance; 87 were found to contain ingredients not declared, resulting in product confiscation and fines averaging 500,000 RMB per violation. The local 药品监督管理局 (Drug Administration, yàopǐn jiāndū guǎnlǐ jú) offices in provinces like Zhejiang and Jiangsu are notably stricter than their counterparts in Beijing or Shenzhen.

Decision Framework for Foreign Cosmetics Executives

Use the following logic to determine your optimal China market entry strategy:

If your product is a general cosmetic (no sunscreen, whitening, anti-aging, or children’s claims), choose the exemption route. This applies to approximately 78% of imported cosmetic filings. You will need a Chinese legal entity to file the notification and must ensure every ingredient is listed in the Existing Cosmetic Ingredient Inventory.

If your product is a special-use cosmetic (sunscreen, whitening, anti-aging, hair dye, children’s), choose the full registration route with animal testing. Prepare for 12–18 months of regulatory processing and testing costs of 400,000–800,000 RMB per SKU. Partner with a Chinese CRO (Contract Research Organization) that has NMPA-accredited testing facilities.

If your product contains new ingredients (not in the inventory), choose the ingredient registration route first. This is the most expensive path, costing 1,000,000–3,000,000 RMB per new ingredient and requiring 2+ years. Consider reformulating using existing ingredients to bypass this requirement.

3 Critical Pitfalls in China Cosmetics Animal Testing Compliance

Pitfall: Relying on the exemption for products marketed as “natural” or “organic” without verifying ingredient inventory status. Many natural extracts are not in the Existing Cosmetic Ingredient Inventory and require new ingredient registration. Cost: Customs rejection leads to product holding fees of 50,000–150,000 RMB per shipment plus 3–6 months delay. Fix: Conduct a pre-filing ingredient audit with a Chinese regulatory consultant to confirm every component is in the inventory.
Pitfall: Using marketing claims that inadvertently classify a general product as special-use. For example, claiming “brightening” on a moisturizer can trigger whitening (special-use) classification. Cost: Reclassification forces animal testing costs of 400,000–800,000 RMB and a 12-month delay. Fix: Review all label claims with an NMPA-compliant translator before filing; use only approved wording from the NMPA’s cosmetics claim dictionary.
Pitfall: Assuming exemption applies to all sales channels. Cross-border e-commerce (CBEC) channels like Tmall Global and JD Worldwide currently do not require animal testing for general cosmetics, but physical retail (offline) does require notification with exemption eligibility. Cost: Selling in offline channels without notification can result in fines of 200,000–1,000,000 RMB and product seizure. Fix: Maintain separate compliance pipelines for CBEC (notify only) and offline retail (full registration with exemption filing).

Case Study: L’Oréal, Estée Lauder, and The Body Shop

L’Oréal has leveraged the exemption for over 60 of its general cosmetic SKUs in China, saving an estimated 20 million RMB in testing costs since 2021. The company maintains a dedicated regulatory team in Shanghai that pre-screens every new product for ingredient inventory compliance and claim classification.

Estée Lauder took a different approach, reformulating its Advanced Night Repair serum to remove three ingredients that were not in the inventory, allowing it to qualify for exemption and reducing time-to-market from 18 months to 4 months.

The Body Shop, which built its global brand on being “cruelty-free,” faces the most acute challenge. Because China’s exemption program is not recognized as “cruelty-free” by international standards (the company’s animal testing policy requires zero testing anywhere, including for registration), The Body Shop has restricted its China presence to CBEC only, avoiding physical retail entirely. This limits its addressable market by approximately 70% compared to brands that accept in-market testing.

Future Trends: What Executives Should Watch

The NMPA has signaled that by 2026, it may expand the exemption to include limited special-use categories for “well-characterized” ingredients, potentially reducing mandatory testing by another 30%. However, enforcement against new ingredients and functional claims is expected to tighten, not loosen. Brands that invest now in ingredient inventory-aligned formulations and claim compliance will be best positioned.

Additionally, 3 out of 5 major Chinese CROs now offer non-animal alternative testing methods (e.g., reconstructed human epidermis models) for safety assessment, though these are not yet accepted by NMPA for registration purposes. We expect regulatory acceptance of these alternatives by 2027–2028, aligning China more closely with EU and US standards.

NEXT STEPS

  1. Audit your product portfolio against the Existing Cosmetic Ingredient Inventory. Identify which products qualify for exemption and which will require full registration. Use our China Cosmetics Registration Guide to map the filing process.
  2. Review your marketing claims for NMPA compliance. Ensure no claim triggers special-use classification. Download the NMPA Cosmetic Claims Dictionary for approved wording.
  3. Engage a Chinese regulatory partner for pre-filing audits. Avoid customs rejection and fines. Schedule a free 30-minute consultation with our China regulatory team to assess your specific compliance path.

— China Gateway 360 —
Remote China market entry support, built around execution.

Related articles

China Cosmetics Update: IECIC Ingredient Additions — Key Takeaways

China Cosmetics Update: 137 New Ingredients Added to IECIC — What Brands Need to Know Now On March 21, 2024, China’s National Institutes for Food and

China Beauty Update: Xiaohongshu Algorithm Changes — Key Takeaways

China Beauty Update: Xiaohongshu Algorithm Changes — Key Takeaways As of March 2025, Xiaohongshu (小红书, Xiaohongshu, xiǎohóngshū) has implemented a maj

China Cosmetics Update: New Animal Testing Rules — Key Takeaways

China Cosmetics Update: New Animal Testing Rules — Key Takeaways China’s National Medical Products Administration (NMPA) significantly expanded animal

China Beauty Update: NMPA Filing Changes in 2026 — Key Takeaways

China Beauty Update: NMPA Filing Changes in 2026 — Key Takeaways On 28 January 2025, China’s 国家药品监督管理局 (National Medical Products Administration, NMPA